Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Treat Complex Generics More Like NDAs In GDUFA III, Teva Says
As GDUFA III Virtual Public Meeting Kicks Off
Jul 23 2020
•
By
Sue Sutter
FDA AND INDUSTRY WANT TO USE THE SUCCESSES OF GDUFA II AS A SPRINGBOARD TO A NEW GENERIC DRUG USER FEE AGREEMENT. • Source: Shutterstock
More from Generics
More from Products